Straight from the horse’s mouth—both sides
by Jon Rappoport
March 24, 2020
“Positive [test] results are indicative of active infection with 2019-nCoV but do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.”
I’m going to blow past the blatant contradiction in that CDC paragraph and cut to the chase.
The key line in that paragraph is: “The agent detected [the coronavirus] may not be the definite cause of disease.”
Here’s what the CDC says about the test for the Coronavirus
Note: The VIRUS as the smokescreen!
Sir Patrick Vallance FRS FMedSci FRCP is Government Chief Scientific Adviser (GCSA) and Head of the Government Science and Engineering (GSE) profession.
Patrick was President, R&D at GlaxoSmithKline (GSK) from 2012 until 2017. Prior to this, he was Senior Vice President, Medicines Discovery and Development. He joined the company in May 2006 as Head of Drug Discovery. He was a member of the GSK Board and the Corporate Executive Team. During his period as head of R&D over 14 new medicines were approved for use worldwide, for diseases ranging from cancer to asthma and HIV.
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases
I was looking at this page – SARS-CoV-2 Coronavirus and patents – on the ABG (European IP firm) firm site.
It mentions Gilead Sciences. This got me interested in GILD’s current stock price. $70.11
…Gilead Sciences, a US biopharmaceutical company that holds several patents and patent applications for potential treatments of coronavirus infections. For example, the international patent application WO 2017/049060 A1, on behalf of this company, contains claims generically addressed to the use of remdesivir in infections caused by viruses of the Coronaviridae family, to which coronaviruses belong
1 year window. Jan 2020 around $65, to a peak of $81.